Category: 3. Business

The European Commission has approved, under EU State aid rules, a €260 million Belgian measure in favour of Air Liquide Large Industry NV (‘Air Liquide’) and BASF Antwerpen NV (‘BASF’) for a carbon capture and storage (‘CCS’) project, Kairos@C. The measure will contribute to Belgium’s climate targets by decarbonising the industry through an integrated cross-border CCS value chain, in line with the objectives of the Clean Industrial Deal.

The project aims at capturing greenhouse gas (‘GHG’) emissions from the companies’ existing plants, located in Antwerp, that produce hydrogen, ammonia and ethylene oxide. The CO₂ captured will be transported to a permanent underground storage site in the North Sea. The project aims to create an integrated, cross-border CCS value chain at industrial scale, which will result in around 20 million tonnes of net GHG emissions avoided, over 15 years. This innovative project will allow the beneficiaries to produce low-carbon hydrogen and low-carbon ammonia.

Click here to read more

Translation: IATA lanza DG Digital para el proceso electrónico de las declaraciones de mercancías peligrosas (pdf)

Lima – The International Air Transport Association (IATA) has launched DG Digital, IATA’s digital Dangerous Goods Declaration solution, as a feature of DG AutoCheck. The new tool fully digitalizes the creation and approval of shippers’ declarations for more than 3,800 dangerous items—from lithium batteries to explosives and chemicals. This results in faster document sharing, improved safety, and a significant reduction in rejected shipments.

Today, 95% of Dangerous Goods Declarations are still received in paper format. These declarations must be scanned, converted into a PDF document, then uploaded into DG AutoCheck to be validated. With DG Digital, declarations are generated and transmitted digitally from creation by the shipper to validation. This creates a more efficient and streamlined workflow compared with traditional paper-based processes.

Digital Declarations

 

DG Digital captures all required data needed for Dangerous Goods Declarations while enabling users to exchange this information electronically with all partners.

Cross-referencing IATA’s Dangerous Goods Regulations (DGR), users of DG Digital can easily identify and address issues that may cause a shipment to be rejected or delayed by an airline, including missing or incorrect documents. Having Dangerous Goods Declarations confirmed before the physical shipment takes place also helps avoid costly fines while addressing any safety concerns.

DG Digital will further support a seamless and safer logistics and transport supply chain by enabling standardized, transparent data exchange across air cargo stakeholders, communities, and platforms.

Successful Trial

 

The launch of DG Digital follows successful trials in Japan last year where digitally validating declarations resulted in only 0.5% of dangerous goods shipments being rejected. This is a significant improvement from the current global average of 4.5% of shipments being rejected due to incomplete or inaccurate declarations. The trial included All Nippon Airways (ANA), Japan Airlines (JAL), and six freight forwarders— International Cargo Service, JAS Forwarding Japan, MOL Logistics, Nippon Express, Nissin, and Yusen Logistics.

Growing Market

 

Since its launch in 2019, DG AutoCheck has completed more than one million dangerous goods checks, with more than a third completed in 2025. This reflects a significant growth in dangerous goods shipments, with data from IATA CargoIS showing a 17.5% year-on-year increase for the full year 2025, largely driven by the growing demand for lithium batteries.

“IATA’s Dangerous Goods Regulations are focused on reducing complexity and improving safety in the shipment of dangerous goods. DG Digital supports this by digitalizing the shipper’s declaration process, providing all stakeholders—from shipping agents and freight forwarders to ground handlers and airlines—access to the same document. This supports the rapid resolution of any issues in the documentation before an item is physically shipped,” said Frederic Leger, IATA’s Senior Vice President, Product & Services.

 

For more information, please contact:

Corporate Communications

Tel: +41 22 770 2967

Email: corpcomms@iata.org

About this report

Keynotes and panel sessions will explore AI-enabled translational safety, real-world evidence integration and clinical enterprise modernization

PHILADELPHIA, March 12, 2026 /PRNewswire/ — TransCelerate BioPharma (TransCelerate), a nonprofit organization dedicated to improving the health of people around the world by accelerating and simplifying clinical research, will play a leading role at PHUSE US Connect 2026, contributing to discussions on clinical innovation, AI and real-world evidence through two conference keynotes and additional leadership and panel sessions.

Held March 22–26 in Austin, Texas, PHUSE US Connect convenes the clinical data science community to advance innovation in data-driven development. TransCelerate’s participation reflects its continued commitment to advancing cross-industry collaboration and delivering practical, implementable solutions that accelerate and simplify clinical research while strengthening patient safety.

Lilliam Rosario, Ph.D., Program Director at TransCelerate and former Director of the FDA’s Office of Computational Science, and Rob DiCicco, Vice President, Portfolio Management at TransCelerate, will each deliver keynote addresses during the conference, highlighting the evolving role of AI, real-world data and cross-industry collaboration in modernizing clinical development.

Rosario will present “Patients First: Collaboration and Innovation Shaping the Future of Safe and Effective Medicines,” on March 26 at 9:00 a.m. CT. Drawing on her experience leading FDA’s computational science efforts, Rosario will explore how shared data standards, structured digital workflows, and improved collaboration across the development lifecycle can reduce uncertainty, strengthen regulatory confidence and support safer, more patient centered development decisions.

“Translational safety, in particular, depends on how effectively we align data, standards and collaboration across the industry,” said Rosario. “PHUSE brings together the leaders shaping clinical data science, making it a timely venue to advance these conversations and support innovation that leads to safer outcomes for patients.”

DiCicco will deliver his keynote, “Modernizing the Clinical Trials Enterprise: Evidence Generation in the Next 10 Years,” on March 25 at 9:00 a.m. CT as part of the Real-World Evidence Pavilion. His keynote will examine why the promise of the Twenty-First Century Cures Act to leverage electronic health data has yet to be fully realized, and how advances in technology and cross-industry collaboration can accelerate modern, scalable evidence generation across the clinical trials enterprise.

In addition to their keynote addresses, both leaders will participate in panel discussions throughout the conference. On March 23 at 4:00 p.m. CT, Rosario will join “From Knowledge to Harnessing Insight: Rethinking Learning, Systems, and Growth through Personal Knowledge Management,” exploring how organizations can move beyond traditional knowledge management to foster adaptive learning cultures that turn information into actionable insight. She will also take part in “Lead the AI Era – Act Now, Transform Pharma: From Data to Breakthroughs,” on March 25 at 4:00 p.m. CT, where senior leaders will discuss scaling AI-driven transformation responsibly, balancing innovation with governance while building trust and organizational capability.

That same day, DiCicco will join the panel discussion “Transforming Real-World Evidence: Integrating AI, Digital Health and Patient-Centric RWE” at 9:45 a.m. CT, exploring how AI and digital health technologies are advancing real-world evidence strategies and translating diverse data into actionable insights across healthcare systems and regulatory settings. Later that afternoon, he will also participate in a session examining how standards organizations are working together to advance interoperability across research and care, challenging persistent myths and highlighting real-world examples of alignment and collaboration.

Meet with TransCelerate at PHUSE US Connect
Media interested in meeting with TransCelerate at PHUSE US Connect are welcome to contact Hannah Davis at [email protected] to schedule a meeting.

About TransCelerate BioPharma Inc.
TransCelerate BioPharma (TransCelerate) is a nonprofit organization that fosters collaboration across the global biopharmaceutical research and development community to simplify clinical trials and help bring new treatments to patients faster, safer, and more efficiently. 
Headquartered in the Philadelphia area, TransCelerate has 18 member companies and a robust portfolio of initiatives focused on transforming connectivity, enabling information sharing and reuse, and driving innovative trial designs. For more information, please visit https://www.transceleratebiopharmainc.com/who-we-are/.

SOURCE TransCelerate BioPharma

• Preliminary observations of the INVINCIBLE-4 Study to date showed that five (5) out of seven (7) patients (71.4%) who received INT230-6 prior to standard of care (“SOC”) (“Cohort A”) achieved a pathological complete response (“pCR”) whereas two (2) out of six (6) (33%) patients in the SOC arm alone (“Cohort B”) achieved a pCR, with one patient still to be evaluated.
   
• Forty-four percent (44%) fewer grade 3 or higher Adverse Events (“AEs”) were observed in Cohort A compared to Cohort B.
• A protocol amendment has been submitted to the Swiss Agency for Therapeutic Products (“Swissmedic”), Switzerland’s regulatory authority, and the Swiss Ethics Committee to resume enrollment.

SHELTON, Conn., March 12, 2026 /PRNewswire/ — Intensity Therapeutics, Inc. (Nasdaq: INTS) (“Intensity” or “the Company”), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and increase immune system recognition of cancers, provided an update on the INVINCIBLE-4 Study. In September 2025, enrollment was paused by the Company due to skin irritations observed in Cohort A. In early March 2026, a protocol amendment was submitted to Swissmedic and the Swiss Ethics Committee to resume enrollment using a lower drug volume per tumor volume ratio and a single injection of INT230-6.

The SOC in the INVINCIBLE-4 Study is the Keynote-522 study regimen, a 6-month presurgical treatment consisting of pembrolizumab every three weeks, then paclitaxel, followed by carboplatin and 4 doxorubicin or epirubicin with cyclophosphamide. The INVINCIBLE-4 Study enrollment criteria is limited to patients with tumors sizes ≥ 1.5 cm, whereas the Keynote-522 study enrolled tumors > 1.0 cm.  As a result, patients in the INVINCIBLE-4 Study, on average, have larger tumors than patients in the Keynote-522 study. Patients undergo the Keynote-522 regimen in an attempt to obtain a pCR, which has been shown to significantly reduce the risk of disease recurrence. pCR is an endpoint that the U.S Food and Drug Administration (“FDA”) and the European Medicines Agency could allow for an accelerated or conditional marketing approval.

Overall, fourteen (14) patients have been treated to date in the INVINCIBLE-4 Study, with seven (7) in each cohort. The expected total enrollment is up to sixty-one (61) patients.  Preliminary observations for the fourteen patients treated to date are as follows:

pCR Data Observations

• Cohort A: A pCR was achieved in five (5) out of seven (7) patients (71.4%) who received injections of INT230-6 prior to SOC. Six (6) patients received two (2) injections and one patient, who achieved a pCR, received one (1) injection.
• Cohort B: A pCR was achieved in two (2) out of six (6) patients (33%) who received the SOC alone, with one patient still to be evaluated.

The pCR analysis is ongoing, and results are preliminary and early.

Safety Data Observations (through March 2, 2026)

• Cohort A: There has been a total of fourteen (14) grade 3 or higher AEs, only one (1) of which is considered a common immune-related side effect of checkpoint immunotherapy.
• Cohort B: There has been a total of twenty-five (25) SOC-related grade 3 AEs, of which four (4) are considered common or rare side effects of immune checkpoint inhibitors (three grade 3 and one grade 4).

The safety data for patients who received INT230-6 plus SOC remain favorable compared with SOC alone.

In the Company’s first presurgical Breast Cancer study completed in 2023 (the “INVINCIBLE-2 Study”), fifty-eight (58) women received one (1) to three (3) injections of only INT230-6. Additionally, skin issues were rare, and surgery was performed without complications.

The Company expects presentation of more detailed results for the seven (7) Cohort A patients at a future oncology conference.

Lewis H. Bender, Founder, President & CEO, said, “The pCR data observations to date in the INVINCIBLE-4 study are promising, though preliminary and early. We are also pleased to see fewer total grade 3 or higher adverse events and fewer adverse events associated with checkpoint inhibitors when our drug is combined with immunochemotherapy in Cohort A than seen in Cohort B. The safety observed to date is consistent with our prior results using our drug with immunotherapy in mice¹ and humans, which have been presented at oncology conferences or published in peer-reviewed journals.”²      

Mr. Bender continued, “Triple-negative breast cancer is one of the most aggressive and difficult to treat subtypes. As reported in the Keynote-522³ study, 77% of patients using the current SOC immunochemotherapy regimen alone have grade 3 or higher systemic adverse events, and 0.5% of patients died from the regimen. Reducing the total number of grade 3 or higher adverse events by 44%, especially immune-related adverse events, and the potential for a higher pCR rate with INT230-6 prior to SOC, could be life-saving for patients. With the amendment now filed with Swissmedic, we look forward to dosing the next patient.”

About Triple Negative Breast Cancer in the Presurgical Setting

Women with aggressive forms of breast cancer, such as Triple Negative Breast Cancer (“TNBC”), are often counseled to undergo pre-surgical (neoadjuvant) systemic therapy in advance to reduce the risk of the disease returning. Having a pathological complete response, meaning the absence of live cancer at the time of surgery, has been shown to result in a lower risk of disease recurrence from 50% to 16% at 5 years. Approximately 11 to 17% of breast cancers test negative for estrogen receptors (“ER”), progesterone receptors (PR), and overexpression of human epidermal growth factor receptor 2 (“HER2”) protein, qualifying them as triple negative. There are approximately 56,000 new cases of TNBC in the US and 420,000 worldwide diagnosed each year, 85% of which are local to the breast. TNBC is considered to be more aggressive and has a poorer prognosis than other types of breast cancer, because there are fewer available targeted medicines. Most patients with local TNBC typically receive immunochemotherapy before surgery. Since the publication of Keynote-522, the standard neoadjuvant treatment for TNBC includes systemic chemotherapy (anthracyclines, cyclophosphamide, paclitaxel, carboplatin) and the anti-PD-1 monoclonal antibody pembrolizumab. pCR rates range from 50 to 65%, depending on tumor size. Rates are generally lower in the larger-sized tumors or with lymph node metastasis. The toxicity of the Keynote-522 regimen is high, with 77% of patients experiencing grade 3 or higher treatment-related AEs, including treatment-related adverse events that lead to death in 0.5% of patients. 

About a Potential INT230-6 Approval Pathway in the Presurgical Setting

The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions and that fill an unmet medical need based on a surrogate endpoint. pCR is an accepted FDA accelerated approval criterion for approval in high-risk breast cancer, such as TNBC subtype. Pathological complete response is defined as the absence of residual invasive and in situ cancer after evaluation of the completely resected breast specimen and lymph nodes following completion of neoadjuvant systemic therapy. If a product is approved using pCR, companies must still seek full approval using event-free survival as an endpoint.

About INT230-6

INT230-6, Intensity’s lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity’s proprietary DfuseRx℠ technology platform. The drug consists of two proven, potent anti-cancer agents, cisplatin and vinblastine sulfate, and a diffusion and cell penetration enhancer molecule (“SHAO”) that non-covalently conjugates to the two payload drugs, facilitating the dispersion of potent cytotoxic drugs throughout tumors and allowing the active agents to diffuse into cancer cells. These agents remain in the tumor, resulting in a favorable safety profile. In addition to local disease control and direct tumor killing, INT230-6 causes a release of a bolus of neoantigens specific to the malignancy, leading to immune system engagement and systemic anti-tumor effects. Importantly, these effects are mediated without immunosuppression, which often occurs with systemic chemotherapy.

About the INVINCIBLE-4 Study

The INVINCIBLE-4 study is a Phase 2 non-comparative, hypothesis-driven randomized open-label, two-cohort multicenter study to analyze the clinical activity, safety, and tolerability of INT230-6 given before administration of the SOC immunochemotherapy treatment in patients with early-stage, operable triple-negative breast cancer and SOC alone. The primary endpoint is the pathological complete response rate for the combination and the SOC alone. pCR is the absence of cancer at the time of surgery in the tumor and nodes. pCR is an FDA accelerated approval endpoint. Clinical evidence is strong that the risk of a patient’s cancer returning is significantly reduced when there is a pCR at the time of surgery.  The Swiss Medic and the European Medicines Agency authorized the initiation of the INVINCIBLE-4 Study in Switzerland and France. The SCI led study is also being done in collaboration with Unicancer (UCBG), the French referent cooperative group in breast cancer accredited by the French National Cancer Institute. The expected total enrollment is up to sixty-one (61) patients.

About Intensity Therapeutics

Intensity is a late-stage clinical biotechnology company whose novel engineered chemistry enables aqueous cytotoxic-containing drug formulations to mix and saturate a tumor’s dense, high-fat, pressurized environment following direct intratumoral injection. As a result of the saturation, Intensity’s clinical trials have demonstrated the ability of INT230-6 to kill tumors and elicit an adaptive immune response within days of injection, representing a new approach to cancer cell death that holds the potential to shift the treatment paradigm and turn many deadly cancers into chronic diseases even for malignancies that do not respond to conventional immunotherapy. Intensity has completed two clinical studies that enrolled over 200 patients using INT230-6: a Phase 1/2 dose escalation study in metastatic cancers including sarcomas (NCT03058289), and a Phase 2 randomized control clinical trial in locally advanced breast cancer (the “INVINCIBLE-2 Study”) (NCT04781725) in women without undergoing chemotherapy prior to their surgery. The Company initiated a Phase 3 trial in soft tissue sarcoma (the “INVINCIBLE-3 Study”) (NCT06263231), testing INT230-6 as second or third-line monotherapy compared to the SOC with overall survival as an endpoint. Intensity also initiated a Phase 2 study in collaboration with The Swiss Group for Clinical Cancer Research, formerly SAKK, now the Swiss Cancer Institute (the “INVINCIBLE-4 Study”) (NCT06358573) as part of a Phase 2/3 program evaluating INT230-6 followed by the SOC immunochemotherapy and the SOC alone for patients with presurgical triple-negative breast cancer. pCR is the endpoint. For more information about Intensity, including publications, papers, and posters about its novel approach to cancer therapeutics, visit www.intensitytherapeutics.com or review our SEC filings.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the Company’s expected future plans, cash runway, development activities, projected milestones, business activities or results. When or if used in this communication, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to the Company or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management’s current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions, and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the initiation, timing, progress and results of future preclinical studies and clinical trials and research and development programs; the need to raise additional funding before the Company can expect to generate any revenues from product sales; plans to develop and commercialize product candidates; the timing or likelihood of regulatory filings and approvals; the ability of the Company’s research to generate and advance additional product candidates; the risk that product candidates that appear promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials; the implementation of the Company’s business model, strategic plans for the Company’s business, product candidates and technology; commercialization, marketing and manufacturing capabilities and strategy; the rate and degree of market acceptance and clinical utility of the Company’s system; the Company’s competitive position; the Company’s intellectual property position; developments and projections relating to the Company’s competitors and its industry; the Company’s ability to maintain and establish collaborations or obtain additional funding; expectations related to the use of cash and cash equivalents and investments; our potential inability to satisfy the Nasdaq Capital Market’s requirements for continued listing and be subject to delisting; estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other risks described in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and in the Company’s subsequent SEC filings, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

Investor Relations Contact:

Justin Kulik
CORE IR
[email protected]
(516) 222-2560

Media Contact:

Matt Cossel
CORE IR
[email protected]

¹ Bloom, Bender, OncoImmunology June 2019
² Thomas_ASCO_2022_poster
³ Shmid_NEJM_2020;

SOURCE Intensity Therapeutics Inc.

Munich/Cologne, 12 March 2026 – The Nemetschek Group, a leading software provider for the AEC/O and media industries, will be exhibiting at digitalBAU 2026 in Cologne from March 24 to 26, 2026, with a clear focus on artificial intelligence (AI). The trade fair presence will spotlight practical innovations from the Nemetschek brands ALLPLAN, Bluebeam, dRofus/dTwin, Graphisoft, Maxon, Nevaris, Solibri, Spacewell, and Vectorworks, as well as from the AI & Data Innovation Hub, all aimed at further accelerating digital processes along the entire building lifecycle.

AI becomes productive – from design to building operations

A central trend at digitalBAU 2026 is the consistent use of artificial intelligence in real-world project workflows. The Nemetschek Group is advancing its group-wide AI Strategy 2026 with three clear priorities: agent-based AI systems, intelligent automation, and product-specific AI functionalities for architecture, design, construction, and operations.

With the Nemetschek AI Assistant, which has been gradually rolled out across all brands since 2025, users benefit from AI-powered assistance that optimizes workflows and provides intelligent, context-sensitive features.

“Artificial intelligence marks a fundamental transformation for the construction and real estate industry,” says Yves Padrines, CEO of the Nemetschek Group. “At digitalBAU 2026, we will demonstrate how our AIbased solutions provide tangible support to professionals in planning, construction, and operations: through intelligent assistants, automated workflows, and new ways to leverage data more effectively and efficiently across the entire building lifecycle.”

The innovations that the Nemetschek Group and its brands will be presenting at digitalBAU 2026 at booth 8.402 include, among others:

• ALLPLAN showcases groundbreaking AI technologies such as the AI Visualizer V2, AI Coder, and an AIenabled Python API that accelerate visualization, BIM modeling, and parametric design, while the AI Assistant helps new Allplan users become experts faster.
• Bluebeam with Bluebeam Max (coming soon), the next generation of AI-powered solutions for construction execution – including automated checks, intelligent drawing comparison, and seamlessly connected workflows between office and jobsite.
• dRofus/dTwin, showcasing their digital data and twin solutions for fully connected planning and operations processes.
• Graphisoft with its Design Intelligence Strategy, which unites all designers in a seamless and interdisciplinary workflow; the AI Assistant for Archicad, DDScad, and MEP Designer; and Project Aurora, a cloudnative design platform that enables datadriven work and wellinformed decisions from the very first sketch.
• Maxon, expanding its portfolio with Redshift for Vectorworks and the new ArchViz Tools, offering powerful visualization workflows tailored to architecture and design projects.
• NEVARIS demonstrates in the infrastructure sector how a fully integrated IFC workflow supports wellinformed project decisions and presents NEVARIS Connect – a cloudbased selfservice solution for standardized data integration. 123erfasst introduces the new Calculation module, which enables users to create and manage quotes, orders, and invoices directly within the app.
• Solibri, presenting new features for model-based quality management and rule checking.
• Spacewell, showcasing innovative solutions for data-driven building management and smart workplace design.
• Vectorworks with the AI Assistant and AI Visualizer for time-saving solutions, accelerated idea generation, and adaptive design workflows.

 

In addition to an extensive presentation program directly at the booth, the Nemetschek Group will also offer numerous talks as part of the official digitalBAU 2026 conference program.

Tuesday, March 24, 2026

• Design Intelligence Strategy – The Future of Design
  

  • 12:00 – 12:30 | German
  • Speaker: Holger Kreienbrink | Graphisoft

• Think Space, Save Energy – How Modern Space & Energy Management Takes Your Building to the Next Level

  • 12:30 – 12:55 | German
  • Speaker: Björn Otterbach | Spacewell

• Intelligent Architectural Design with Vectorworks and AI

  • 13:00 – 13:25 | German
  • Speaker: Marvin Saeuberlich | Vectorworks/Computerworks

• The Forgotten Middle: Digitalization Between Design and Management

  • 13:30 – 13:55 | German
  • Speaker: Christoph Becker | Bluebeam

 

Wednesday, March 25, 2026

• The Future of Construction: Guiding You into the New Era of Intelligent Building
  

  • 10:00 – 10:30 | English
  • Speaker: Yves Padrines | CEO Nemetschek Group

• Using Maxon Tools for Architectural Visualization and Achieving High-Quality Renderings

  • 12:30 – 12:55 | German
  • Speaker: Jörg Vogel | Maxon

• From Parametric Model to Automated CO₂ Assessment

  • 13:00 – 13:25 | German
  • Speaker: Heinz-Michael Ruhland | Nevaris

• AI for Measurable Performance in the Built World

  • 13:30 – 13:55 | German
  • Speaker: Julian Geiger | Nemetschek AI

• Intelligent Architectural Design with Vectorworks and AI

  • 15:00 – 15:25 | German
  • Speaker: Marvin Saeuberlich | Vectorworks/Computerworks

 

Thursday, March 26, 2026

• AI Power in Digital Design: From First Ideas to Smart Automation
  

  • 10:30 – 10:55 | German
  • Speaker: Marc-Philipp Spiegelberg | ALLPLAN

• Intelligent Architectural Design with Vectorworks and AI

  • 11:00 – 11:25 | German
  • Speaker: Marvin Saeuberlich | Vectorworks/Computerworks

• The Connected Construction Site – From Isolated Solutions to an End-to-End Workflow

  • 11:30 – 11:55 | German
  • Speaker: Philip Knoll | Nevaris

• The Forgotten Middle: Digitalization Between Design and Management

  • 12:00 – 12:25 | German
  • Speaker: Christoph Becker | Bluebeam

 

About digitalBAU 2026

digitalBAU 2026 will take place from March 24 to 26, 2026, at the Koelnmesse exhibition center in Cologne and is one of the leading trade fairs for digital solutions in the construction industry. The event focuses on innovations related to BIM, AI, smart construction, digital design, and connected construction processes. As a key industry meeting place, it brings together designers, construction companies, software providers, and decision-makers and, in addition to the exhibition, offers a comprehensive conference and presentation program with hands-on insights into the future of construction.

About the Nemetschek Group

The Nemetschek Group is a leading global vertical software and AI provider driving the digital transformation of the AEC/O and media industries. With our deep domain expertise and intelligent, connected software solutions, we enable customers to turn data into real-time insights and smarter decisions throughout the entire lifecycle of buildings and infrastructure from ideation through planning, visualization, construction, operation, and renovation. 

Our AI-powered technologies and open standards approach boost productivity, collaboration, and sustainability for architects, engineers, contractors, building operators, and creative professionals. More than 7 million users worldwide rely on our customer-centric, human-led AI solutions. Founded by Professor Georg Nemetschek in 1963, today we employ over 4,000 experts globally and are ISO 27001-certified, underlining our strong commitment to data security and trustworthy digital innovation.

The Nemetschek Group, listed in the MDAX and TecDAX since 1999, achieved a revenue of €1.19 billion and an EBITDA of €371.1 million in 2025, according to preliminary, non-audited figures.

What Is the Significance of This KS Certification?

KS certification is a national system that guarantees products and services conform to set Korea standards. The process is managed by institutions designated by the Korean Agency for Technology and Standards (KATS), with KIRIA overseeing the robotics sector to ensure the safety and reliability of advanced robot products.

This certification is highly significant as it is the first time the quality of a wearable robot has been certified by a nationally recognized standard within Korea’s domestic robotics industry. This officially acknowledges the X-ble Shoulder as a product that meets high safety and quality benchmarks.

What Are the Key Features of the X-ble Shoulder?

The X-ble Shoulder is designed with a non-powered torque-generating structure, making it not only lightweight but also convenient to maintain, as it does not require charging.

By applying a torque generator module, it generates assistive force that can reduce the load on a worker’s shoulder joint by up to 60 percent and the activity of the anterior and lateral deltoid muscles by up to 30 percent.

The X-ble Shoulder has also been widely recognized for its product safety globally. In February 2025, it received the ‘ISO 13482’ certification for safety from DNV (Det Norske Veritas), the European Union’s integrated certification body based in Norway. This was followed in May of the same year by the European Union’s ‘Machinery Directive’ certification, confirming its mechanical safety for industrial use in Europe.

How Is Hyundai Motor Group Advancing Its X-ble Robotics Technology?

Hyundai Motor Group is continuously pursuing the development and commercialization of its human-centered ‘X-ble’ robotics technology series. The X-ble Shoulder is already being applied in various domestic industrial sites, including major Hyundai Motor Group affiliates, Korean Air and the Korea Railroad Corporation (Korail). The business scope for the technology is also expanding, following a business agreement signed in 2025 with the Korean Rural Development Administration.

Development is also underway for other wearable robots:

• The X-ble Waist is being developed to reduce the burden on workers who handle heavy materials in industrial environments.
• The X-ble MEX, a medical wearable robot that assists with the mobility of patients with lower-limb paralysis, is undergoing research and development for use in rehabilitation and medical fields.

Baker McKenzie has advised the lender syndicate comprising of six banks on a THB 28 billion facility for the development of one of Thailand’s largest data center projects. The financing was provided to DayOne Data Center’s subsidiary in Thailand.

The green loan will be used to finance the development, construction and operation of a multibuilding data center. The financing has also been structured to comply with green loan principles, with proceeds to be applied towards the development satisfying key eligibility criteria.

The financing is bespoke with structural features customary for large scale project financings in the data center sector. This transaction represents continued growth of the digital infrastructure sector in Thailand.

The Baker McKenzie team was led by Viroj Piyawattanametha (Head of Energy & Infrastructure, Bangkok) and Tatcha Thumpramoth (Partner, Energy & Infrastructure, Bangkok), with key contributions from Hongrat Jungwanitchakun, Roypim Ransigutta and Panisa Daochai.